SavedAdd your journal

Journals / Turkish Respiratory Journal / 2002 / Cilt: 3 - Sayı: 1

Aingle-angel oral etoposide in patients with relapsed or refractory extensive small-cell lung cancer

TUNCAY GÖKSEL
Serdar SOYER
Sezai TAŞBAKAN
Ulus Ali ŞANLI
Mahmut ATEŞ
Erdem GÖKER
Pages
15–18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Prolonged administration of low-dose oral etoposide is well tolerated in relapsed or refractory SCLC and has thera-peutic efficacy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To evaluate the effectiveness and toxicity of prolonged low-dose oral etoposide in patients with relapsed or refrac-tory extensive small-cell lung cancer.
📊
Key Findings & Data:Patients and Design: Thirty-one patients with relapsed or refractory extensive SCLC were treated with oral etoposide 50 mg (25 mg bid) for 14 days every 3 weeks.
💡
Conclusion & Impact:Conclusion: Prolonged administration of low-dose oral etoposide is well tolerated in relapsed or refractory SCLC and has thera-peutic efficacy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Karsinom · küçük hücreli · Etoposid

Abstract

Objective: To evaluate the effectiveness and toxicity of prolonged low-dose oral etoposide in patients with relapsed or refrac-tory extensive small-cell lung cancer. Patients and Design: Thirty-one patients with relapsed or refractory extensive SCLC were treated with oral etoposide 50 mg (25 mg bid) for 14 days every 3 weeks. Response, duration of response, survival and toxicity were evaluated. Setting: Departments of Pulmonary Medicine and Medical Oncology, School of Medicine, Ege University. Complete response was not observed. Median duration of response was 16 weeks. Median survival was 16 weeks (range, 4-48 weeks). Two patients developed grade 3 leukopenia and 6 had grade 1-2 leukopenia. Two patients had grade 1-2 thrombocytopenia One patient developed grade 2 nausea/vomiting, and one patient grade 2 diarrhea. Conclusion: Prolonged administration of low-dose oral etoposide is well tolerated in relapsed or refractory SCLC and has thera-peutic efficacy.

🔖

Cite This Article

GÖKSEL, T., SOYER, S., TAŞBAKAN, S., ŞANLI, U. A., ATEŞ, M., GÖKER, E. (2002). Aingle-angel oral etoposide in patients with relapsed or refractory extensive small-cell lung cancer. Turkish Respiratory Journal, Cilt: 3 - Sayı: 1, 15–18. https://ajindex.com/articles/375338

References (14)

  1. Bunn PA, Camay DN. Overview of chemotherapy for small-cell lung cancer. Semin Oncol 1997; 24 (suppl 7): 69-74
  2. Einhorn LH. Initial therapy with cisplatin plus VP-16 in small-cell lung cancer. Semin Oncol 1986; 13: 5-9
  3. Grant SC, Gralla RJ, Kris MG, et al. Single agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: The case for studies in previ¬ ously treated patients. J Clin Oncol 1992; 10: 484-98
  4. Clark PI, Cottier B. The activity of 10-, 14-, and 21- day schedules of single-agent etoposide in previously untreated patients with small-cell lung cancer. Semin Oncol 1992; 19 (suppl 14): 36-9
  5. Sessa C, Zucchetti M, Tori V et al. Chronic oral etoposide in small-celllung cancer: clinical and farmacokinetic results. Ann Oncol 1993; 4:553-8
  6. De Jong RS, Mulder NH, Dijksterhuis, et al. Review of current clinical experience with prolonged (oral) etoposide in cancer treatment. Anticaricer Research 1995; 15: 2319-30
  7. Katoh O, Yamada H, Hiura K, et al. Clinical pharmacology and toxic¬ ity of low daily administration of oral etoposide in advanced lung can¬ cer patients. J Clin Phamarcol 1991; 31(12): 1155-60
  8. Einhorn LH, Pennington K, McClean J. Phase II trial of daily oral VP- 16 in refractory small-cell lung cancer: A Hoosier Oncology Group Study. Semin Oncol 1990; 17 (suppl 2): 32-35
  9. Johnson DH, Greco FA, Strupp JS, et al. Prolonged administration of oral etoposide in patients with relapsed of refractory small-cell lung cancer: A phase II trial. J Clin Oncol 1990; 8: 1613-7
  10. Fukuoka M, Furuse K, Saijo, et al. Randomized study of cyclophos- phamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991; 83: 855-61
  11. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small- cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10(2): 282-91
  12. Issel BF, Einhorn LH, Comis RL, et al. Multicenter phase II trial of etoposide in refractory small-cell lung cancer. Cancer Treat Rep 1985; 69: 127-8
  13. Antman K, Pomfret E, et al. Phase II trial of etoposide in previously treated small-cell carcinoma of the lung. Cancer Treat Rep 1984; 68: 1413-4
  14. Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (Taxotere) in small-cell lung cancer. Eur J Ca